Chronic wounds, especially diabetic foot ulcers (DFUs), venous leg ulcers, and pressure injuries, remain a major global challenge, often recurring at the ...

Kodiak Sciences’ KOD shares have surged 24% over the past three months, driven by strong momentum around its late-stage pipeline and improving financial position, which have boosted investor ...

Indian researchers reveal how immune cells 'betray' the body, aiding breast cancer spread and suggesting new treatment ...

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, ...

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

Strength training strengthens muscles, improves blood glucose control, and is said to reduce the risk of cardiovascular ...

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, ...

Cancer is one of the causes responsible for the most deaths worldwide; in 2020, for example, it resulted in ten million deaths. It has been estimated that micro-organism infections caused between ...

Cancer is one of the causes responsible for the most deaths worldwide. In 2020, for example, it resulted in ten million ...

North America remains the dominant market, driven by high healthcare expenditure, advanced R&D infrastructure, and early adoption of innovative therapies. The region’s focus on oncology and ...

The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...